DNA to RNA (D2R)
An inclusive Canadian approach to RNA therapeutics
McGill University is proud to announce it has been awarded $165 million from the Canadian Government through the Canada First Research Excellence Fund (CFREF) to pursue its world leading genomically-driven RNA therapeutics research initiative. The largest research grant in McGill’s history, the D2R initiative leverages McGill’s decades-long expertise in DNA and RNA research to develop the next generation of RNA medicines. With the goal of developing novel therapeutics for viral infections, cancer, and rare diseases, we aim to help restore Canada’s capacity in biopharmaceutical production, while also ensuring the treatments are shared equitably.
Here is a look at McGill’s game-changing research and the people behind the science.